Earnings Call · Q2 FY2023·2023-08-07

Q2 23EPS -7.41%·Rev n/aQ1 23EPS +3.92%·Rev n/aQ4 22EPS -75.00%·Rev n/aQ3 22EPS 0.00%·Rev n/a⚠ consensus missing

Tvardi Therapeutics, Inc. TVRD

Matthew Murphy — Unknown

Christopher Posner — Chief Executive Officer

Ryan Maynard — Chief Financial Officer

−0.3%1d on move date+0.1% vs SPY3d+4.7%5d+1.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TVRD calls or request research access.

More TVRD calls Browse calls Request research access